Endo International (ENDP)
NASDAQ: ENDP
· Real-Time Price · USD
0.37
0.00 (0.79%)
At close: Aug 15, 2022, 10:00 PM
Endo International Revenue Breakdown
| Period Ending | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|
| Sterile Injectables Segment Revenue | 1.27B | 1.24B |
| Sterile Injectables Segment Revenue Growth | +2.20% | n/a |
| Branded Pharmaceuticals Segment Revenue | 893.62M | 781.78M |
| Branded Pharmaceuticals Segment Revenue Growth | +14.31% | n/a |
| Generic Pharmaceuticals Segment Revenue | 740.59M | 783.11M |
| Generic Pharmaceuticals Segment Revenue Growth | -5.43% | n/a |
| International Pharmaceuticals Segment Revenue | 92.91M | 99.34M |
| International Pharmaceuticals Segment Revenue Growth | -6.47% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|
| United States Revenue | 319.46M | 315.05M | 330.09M |
| United States Revenue Growth | +1.40% | -4.55% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 180.83M | 227.16M | 250.1M | 246.86M | 177.62M | 187.17M | 176.22M | 182.26M | 173.26M | 166.77M | 160.67M | 168.33M | 152.3M | 151.12M | 167.42M | 163.79M | 148.16M | 166.67M | 161.2M | 135.88M | 155.56M | 177.24M | 212.57M | 186.74M | 193.07M | 178.35M | 212.01M | 163.22M | 154.49M | 211.58M |
| Selling, General, and Administrative Revenue Growth | -20.40% | -9.17% | +1.31% | +38.99% | -5.10% | +6.22% | -3.31% | +5.20% | +3.89% | +3.79% | -4.55% | +10.53% | +0.78% | -9.74% | +2.22% | +10.55% | -11.11% | +3.39% | +18.63% | -12.65% | -12.23% | -16.62% | +13.83% | -3.28% | +8.25% | -15.88% | +29.89% | +5.65% | -26.98% | n/a |
| Research and Development Revenue | 29.79M | 36.13M | 58.54M | 25.62M | 34.67M | 29.74M | 64.74M | 32.05M | 30.5M | 31.61M | 34.38M | 36.52M | 26.35M | 33.49M | 25.39M | 39.68M | 82.1M | 38.65M | 48.55M | 39.64M | 40.87M | 43.01M | 46.21M | 44.88M | 50.59M | 41.69M | 43.99M | 21.33M | 18.98M | 17.9M |
| Research and Development Revenue Growth | -17.55% | -38.28% | +128.51% | -26.11% | +16.58% | -54.06% | +101.96% | +5.12% | -3.54% | -8.04% | -5.86% | +38.60% | -21.32% | +31.86% | -36.01% | -51.67% | +112.45% | -20.39% | +22.45% | -3.00% | -4.98% | -6.92% | +2.94% | -11.28% | +21.34% | -5.22% | +106.26% | +12.34% | +6.07% | n/a |